• Skip to main content

DistilGovHealth

DistilNFO GovHealth Advisory

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

CMS proposes continuing new technology add-on payments for CAR-T cell therapies next year

Share:

April 30, 2019

The agency also proposed increasing the maximum new technology add-on payment from 50 percent to 65 percent for fiscal year 2020.

The Centers for Medicare and Medicaid Services is proposing to continue the extra payments it gives to the two Food and Drug Administration-approved CAR-T cell therapies based on their high costs.

In its fiscal year 2020 proposals for the Inpatient Prospective Payment System, CMS proposed continuing the new technology add-on payments for the CAR-Ts, Novartis’ Kymriah (tisagenlecleucel) and Gilead Sciences’ Yescarta (axicabtagene ciloleucel). It additionally proposed increasing the maximum for new technology add-on payments for CAR-Ts from 50 percent to 65 percent, or from $185,500 to $242,450.

The policy is designed to provide additional payments for high-cost medical treatments while preserving the existing average-based payment system. That’s especially important for therapies like CAR-Ts, whose list prices alone run well into the hundreds of thousands of dollars. Yescarta and Kymriah each carry a list price in adult diffuse large B-cell lymphoma of $373,000, while Kymriah for pediatric acute lymphoblastic leukemia – a disease in which it has higher odds of being effective – costs $475,000. That doesn’t include supportive care costs for things like inpatient stays and treating potentially dangerous side effects like cytokine release syndrome and neurotoxicity, which can exceed the list prices themselves.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

In its proposal, CMS noted that it was inviting public comment on other payment alternatives for CAR-T therapies in 2020.

ALL is more common in children and young adults than in older adults, with 4-in-10 cases occurring in older adults, according to the American Cancer Society, which estimates there will be 5,930 new cases in the US this year. Kymriah is approved for children and young adults who aren’t cured through existing treatments. According to St. Jude’s Children’s Research Hospital, about 98 percent of children with ALL go into remission, and about 90 percent of them achieve a cure, defined as 10 years of remission. DLBCL occurs in 5.6 people per 100,000 per year, according to the National Cancer Institute, with 63.2 percent of patients surviving five years.

While pediatric ALL and adult DLBCL thus represent relatively small markets, CAR-T therapies are expected to see an explosion in use when they become available for solid tumor cancers, though solid tumor CAR-Ts remain far behind in development compared with blood cancers. The next disease state likely to see a CAR-T reach the market is the blood cancer multiple myeloma. For that cancer, bluebird bio and Celgene’s bb2121 is in the lead, with the FDA expected to rule on its approval next year.

Date: May 01, 2019

Source: MedCityNews

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Major Payers Find HHS Finalized Nondiscrimination Rule Too NarrowMajor Payers Find HHS Finalized Nondiscrimination Rule Too Narrow
  • New Clinically Validated Sleepcheck App LaunchesNew Clinically Validated Sleepcheck App Launches
  • Apple Still has a Lot of Room to Grow in the $3.5 Trillion Health Care SectorApple Still has a Lot of Room to Grow in the $3.5 Trillion Health Care Sector
  • Google Moves Further Into Healthcare: a Timeline of the Last YearGoogle Moves Further Into Healthcare: a Timeline of the Last Year
  • Superb Healthcare At Ultra-Low Prices? How Singapore Does ItSuperb Healthcare At Ultra-Low Prices? How Singapore Does It
  • AI, Machine Learning, and Blockchain are Key for Healthcare InnovationAI, Machine Learning, and Blockchain are Key for Healthcare Innovation

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications